<DOC>
	<DOCNO>NCT03017729</DOCNO>
	<brief_summary>The purpose study assess longitudinal attainment subject centre functional related goal ( cumulated Goal Attainment Scale Total ( GAS T ) score ) abobotulinumtoxinA injection ( include follow repeat injection cycle occur ) alongside spasticity management use real life setting period 18 month ( maximum six injection cycle ) .</brief_summary>
	<brief_title>Effectiveness Safety Dysport速 ( abobotulinumtoxinA ) Paediatric Lower Limb Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Female male subject age 2 17 year inclusive Decision prescribe abobotulinumtoxinA , make prior independently decision enrol study Primary diagnosis paediatric low limb ( PLL ) spasticity either : Previously untreated BoNT ( na誰ve BoNT ) , previously treat BoNT ( i.e . non na誰ve BoNT ) , previously treat BoNTA , respond BoNTA treatment accord investigator 's criterion For non na誰ve BoNT subject , minimum interval 12 week since last BoNT injection presence spasticity Known resistance BoNT experience serious safety issue previous use BoNT Concomitant treatment BoNT Known hypersensitivity abobotulinumtoxinA related compound , component study drug formulation Subjects clinical ( subclinical ) evidence mark defective neuromuscular transmission ( e.g . Lambert Eaton syndrome myasthenia gravis ) persistent clinically significant neuromuscular disorder</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>